Ludwig In the News

December 6, 2013
Fox News

A new study has revealed that brain cancer cells can actually evade many current cancer drugs—by temporarily scaling down a certain genetic mutation that the drugs target.

October 11, 2013
National Public Radio

A genetic variation that protects skin against sun damage may also increase the risk of testicular cancer, at least in mice. Researcher Gareth Bond discusses why this relationship may have evolved and how the findings could help to create personalized cancer treatments for humans.

October 10, 2013

A genetic variant that increases the risk of testicular cancer may be favored by evolution because it helps protect those with fair skin from the sun’s damaging ultraviolet rays, according to a new study.

October 1, 2013
Oncology Times

It’s time to give combination immunotherapy a chance against a broader range of cancers. Historically, such strategies have primarily been investigated for melanoma and kidney cancers.

September 23, 2013
Genetic Engineering & Biotechnology News

Scientists from the Ludwig Institute for Cancer Research and the Karolinska Institutet report the development of an improved method for analyzing the genes expressed within a single cell. They say their finding will be relevant for everything from basic research to future cancer diagnostics.

August 15, 2013
AM with Tony Eastley

Australian scientists say they have discovered a molecule which they believe is responsible for the growth of some cancerous tumours. It provides researchers with a new target for anti cancer therapies.

July 10, 2013
Oncology Times

David Lane, PhD, has been named Scientific Director of the Ludwig Institute for Cancer Research. In the new role, which commenced last month, Lane will coordinate Ludwig’s global research efforts and activities.

June 27, 2013
The New York Times

Research demonstrates a little-appreciated but inescapable fact about cancer: It is an evolutionary disease. And studies are provoking new thinking about ways to use drugs to kill cancerous cells.

June 12, 2013

Seattle-based Immune Design took a big step forward as a company in 2010 when it struck a deal to let AstraZeneca’s MedImmune unit test out its proprietary vaccine boosters, or adjuvants. Now, it’s got a bigger goal in mind: using a broad collaboration with two big non-profit organizations to break into the hot field of cancer immunotherapy.

June 12, 2013
News Medical

One protein that keeps healthy cells from behaving this way is a tumor suppressor named p53. This protein stops potentially precancerous cells from dividing and induces suicide in those that are damaged beyond repair. Not surprisingly, p53’s critical function is disrupted or silenced in many cancers.

June 5, 2013
The Age

A large trial combining two drugs for people with advanced melanoma is due to begin at several Australian hospitals in coming months after a small American study of 52 people found the treatment shrank most participants’ tumours.

May 30, 2013

Today, many cancer patients are treated with antibody drugs that work in part by marking tumor cells for destruction by macrophages. Although these drugs have extended lives, they don’t always work very well—partly because cancer cells fight back by sending a “don’t eat me” signal to the immune cells.

May 15, 2013
The New York Times

Cancer researchers are growing increasingly enthusiastic about harnessing the body’s own immune system to fight tumors. And new research shows that two drugs that use this approach may be even better than one.

May 13, 2013
Bloomberg News

Merck & Co., Bristol-Myers Squibb Co. and Roche Holding AG have opened a new front against cancer with the next generation of experimental drugs that use the human immune system to seek and destroy tumor cells.

April 17, 2013

Researchers have identified a mechanism of action that explains why patients with glioblastoma have not had successful outcomes when treated with inhibitors of mammalian target of rapamycin (mTOR) despite the fact that mTOR is overexpressed in approximately 90% of cases of the disease.

April 1, 2013
The Scientist

Tumors that arise in the same organs in humans and fish look and behave alike, and the cancers often share common genetic underpinnings. As a result, most researchers believe that the basic mechanisms underlying tumor formation are conserved across species, allowing them to study the formation, expansion, and spread of tumors in animal models with the hope of eventually finding new insights into cancer in people.

January 9, 2013
The New York Times

The Pap test, which has prevented countless deaths from cervical cancer, may eventually help to detect cancers of the uterus and ovaries as well, a new study suggests.


You are now leaving Ludwig Cancer Research's website and are going to a website that is not operated by the association. We are not responsible for the content or availability of linked sites. Do you wish to continue?